• 

  How Down Syndrome Research Is Helping Scientists Understand Alzheimer’s
• 

  EU Approves Leqembi: Regulators Flip from ‘No’ to ‘Yes’ on Alzheimer’s Drug
• 

  Alzheimer’s Drug Trials: Do Drug Companies Warn You About Your Genetic Risk?
• 

  Trojan Horse: Carrying Alzheimer’s Antibodies Into the Brain
• 

  It Takes Tau to Tangle: Is Faster Buildup Driving Women’s Alzheimer’s Risk?
• 

  In Trials: A Powerful Magnet for Zapping Alzheimer’s Away
• 

  States Propose Bills to Make Private Insurers Cover Approved Alzheimer’s Drugs, Diagnostics
• 

  What Can We Learn About Dementia from LGBTQ+ Brain Health Research?
• 

  Alzheon Alzheimer’s Pill Misses the Mark in Phase 3 Trial, Hints at Benefit in MCI
• 

  After Two Phase 3 Trial Fails, Cassava Sciences Gives Up On Alzheimer’s Drugs
• 

  No Kisunla in Europe: Regulators Reject Lilly’s Alzheimer’s ‘Mab’ Drug
• 

  23andMe to Sell Users’ Genetic Data in Bankruptcy Court — What You Need to Know
• 

  Long COVID 101: Patients and Doctors Explain the Condition
• 

  How Sex Hormones, Chromosomes, and Menopause Affect Women’s Brain Health
• 

  Research Into a COVID-Alzheimer’s Link Continues

Previous789Next